[go: up one dir, main page]

WO2024167307A1 - Composition contenant bifidobacterium longum comme principe actif et servant à la prévention ou au traitement de maladies allergiques - Google Patents

Composition contenant bifidobacterium longum comme principe actif et servant à la prévention ou au traitement de maladies allergiques Download PDF

Info

Publication number
WO2024167307A1
WO2024167307A1 PCT/KR2024/001823 KR2024001823W WO2024167307A1 WO 2024167307 A1 WO2024167307 A1 WO 2024167307A1 KR 2024001823 W KR2024001823 W KR 2024001823W WO 2024167307 A1 WO2024167307 A1 WO 2024167307A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
allergic diseases
preventing
asthma
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2024/001823
Other languages
English (en)
Korean (ko)
Inventor
강기성
임채연
맹재영
성민희
이원석
이동호
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biobankhealing Inc
Original Assignee
Biobankhealing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biobankhealing Inc filed Critical Biobankhealing Inc
Publication of WO2024167307A1 publication Critical patent/WO2024167307A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • Allergic diseases are diseases caused by allergies, which are antigen-antibody reactions that occur when an antigen or allergen (the cause of allergy) enters an organism and antibodies are produced against it, and then the same substance (antigen) enters the body again (Dictionary of Nutrition, March 15, 1998, Chae Beom-seok, Kim Eul-sang).
  • the main diseases are respiratory diseases, dermatitis (including atopic dermatitis), drug allergies, drug allergies, and serum sickness, and various types of diseases appear depending on the type of allergen or the tissue causing the allergic reaction.
  • Allergic respiratory disease refers to respiratory diseases involving allergic reactions, and representative examples include bronchial asthma, bronchitis, and allergic rhinitis.
  • Bronchial asthma is a disease in which the bronchi in the lungs become very sensitive, sometimes narrowing the bronchi, causing shortness of breath and severe coughing. It is an allergic disease caused by an allergic inflammatory reaction in the bronchi. The prevalence of bronchial asthma is on the rise due to recent westernization and changes in eating habits.
  • Bronchitis is an inflammation of the bronchi in the lungs. Unlike acute bronchitis, which is caused by a viral infection in more than 90% of cases, chronic bronchitis is caused by chronic inhalation of highly irritating dust from occupations such as air pollution, coal mining, grain handling, textile manufacturing, livestock farming, and metal casting. It is characterized by wheezing and shortness of breath during exercise, low oxygen saturation, and persistent phlegm and cough for more than two years, lasting more than three months each year.
  • Allergic rhinitis is a disease in which the nasal mucosa shows a hypersensitivity reaction to a specific substance.
  • various types of inflammatory cells mediated by IgE antibodies including mast cells and eosinophils, flock to the stimulated area, causing an inflammatory response through various mediators secreted by them.
  • bronchial asthma has various pathogenesis mechanisms, in which the Th2 (T helper type 2) type immune response is enhanced, which increases the secretion of interleukin-4, 5, and 13 (Liu et al., 2006; Williams et al., 2012), and in conjunction with this response, many inflammatory cells, including eosinophils, migrate and infiltrate into lung tissue (Zhou et al., 2011). In addition, inflammatory cells release various proinflammatory factors and chemotactic factors, which further aggravate the inflammatory response, increase mucus secretion by goblet cells in the airway, and cause airway hyperresponsiveness (Chibana et al., 2008). Due to this series of reactions, patients with bronchial asthma show clinical symptoms such as dyspnea, cyanosis, and chest pain.
  • drugs used to treat allergic diseases include steroid preparations, antihistamines, bronchodilators, and antibiotics.
  • Steroid preparations and antibiotics are used to treat allergic diseases by suppressing immune responses and inflammatory responses, and bronchodilators are used to offset clinical symptoms such as dyspnea when they occur.
  • these drugs have been found to have side effects such as immunosuppression, bone marrow suppression, antibiotic resistance, and side effects when used long-term, so their use as therapeutic agents is very limited.
  • One aspect is to provide a pharmaceutical composition for preventing or treating allergic diseases, comprising as an active ingredient a Bifidobacterium longum strain belonging to the genus Bifidobacterium sp. , an endoplasmic reticulum derived from the strain, a lysate or culture medium of the strain, or a mixture thereof.
  • Another aspect is to provide a health functional food for preventing or improving allergic diseases, which contains as an effective ingredient a Bifidobacterium longum strain belonging to the genus Bifidobacterium sp. , an endoplasmic reticulum derived from the strain, a lysate or culture medium of the strain, or a mixture thereof.
  • Another aspect provides a method for preventing or treating an allergic disease, comprising administering to a subject in need thereof an effective amount of a strain of Bifidobacterium longum belonging to the genus Bifidobacterium sp. , vesicles derived from the strain, a lysate or culture medium of the strain, or a mixture thereof.
  • Another aspect provides the use of a strain of Bifidobacterium longum belonging to the genus Bifidobacterium sp. , an endoplasmic reticulum derived from the strain, a lysate or culture medium of the strain or a mixture thereof, for use in the manufacture of a pharmaceutical preparation for preventing or treating allergic diseases.
  • One aspect provides a pharmaceutical composition for preventing or treating allergic diseases, comprising as an active ingredient a Bifidobacterium longum strain belonging to the genus Bifidobacterium sp. , an endoplasmic reticulum derived from the strain, a lysate or culture medium of the strain, or a mixture thereof.
  • the above Bifidobacterium longum strain may be a strain deposited under the deposit number KCTC 14523BP.
  • the strain may have an effect of preventing, improving or treating allergic diseases.
  • the allergic diseases may be inflammatory respiratory diseases, asthma, allergic asthma, allergic rhinitis, eosinophilic asthma or eosinophilia.
  • the above inflammatory respiratory disease may be any one selected from the group consisting of chronic obstructive pulmonary disease (COPD), acute lung injury, empyema, lung abscess, pneumonia, pulmonary tuberculosis, cough, sputum, bronchitis, pharyngitis, tonsillitis, sinusitis, rhinitis, obliterative bronchiolitis, and laryngitis.
  • COPD chronic obstructive pulmonary disease
  • acute lung injury empyema
  • lung abscess pneumonia
  • pulmonary tuberculosis cough
  • sputum bronchitis
  • pharyngitis tonsillitis
  • sinusitis sinusitis
  • rhinitis obliterative bronchiolitis
  • laryngitis laryngitis
  • the strain may have an effect of alleviating the influx of inflammatory cells.
  • the strain may have an effect of alleviating the influx of inflammatory cells in eosinophilic airway inflammation.
  • the strain may have a great effect of alleviating the influx of eosinophils among inflammatory cells.
  • the strain may have an effect of alleviating cytokine production.
  • the strain may have an effect of reducing IL-4, IL-5, IL-13 and Eotaxin among cytokines.
  • IL-4 and IL-13 are cytokines important for Th2 cell differentiation and immune response.
  • IL-5 and Eotaxin are cytokines important for eosinophil generation and migration.
  • the strain may reduce IL-4 and/or IL-13 or effectively reduce Th2 cell differentiation.
  • the strain may effectively reduce at least one selected from the group consisting of IL-5, Eotaxin and eosinophils.
  • the strain may have an effect of alleviating antibody production in serum.
  • the antibody may be a specific antibody for an allergen.
  • the antibody may be an IgE antibody.
  • the effect of alleviating antibody production may be alleviating the production of a specific antibody for an allergen without affecting the total antibody production and change amount.
  • the strain may have an effect of alleviating inflammatory cell infiltration in lung tissue.
  • the strain may have an effect of alleviating inflammatory cell infiltration in the basal part of blood vessels and alveoli.
  • treat in this specification may mean that allergic diseases, etc. are cured in a shorter period of time compared to natural healing.
  • the treatment may include improvement and/or alleviation of allergic diseases, etc.
  • the treatment may mean cure and/or recovery of symptoms caused by allergic diseases, etc.
  • vesicle refers to a particle secreted from a cell and released into the extracellular space, and may include a number of different species, such as exosomes, ectosomes, microvesicles, microparticles, and exosome-like vesicles.
  • Extracellular vesicles can reflect the state of the secreting source cell (donor cell), exhibit various biological activities depending on which cell they are secreted from, and play an important role in cell-to-cell interaction while transferring genetic material and proteins between cells.
  • cell-derived substances including the vesicles cause diseases or stimulate immune cells to fight diseases, and have the effect of helping humans decompose and absorb substances that they cannot digest through the metabolic process of microorganisms.
  • the above endoplasmic reticulum is a membrane-structured endoplasmic reticulum, which is divided into an inside and an outside, and contains plasma membrane lipids, plasma membrane proteins, nucleic acids, and cytoplasmic components of the cell, and may be smaller than the original cell.
  • the vesicles may be isolated from a cell lysate of a culture medium of a Bifidobacterium longum strain.
  • the extracellular vesicles may have a diameter of 10 nm to 400 nm.
  • culture medium may be used interchangeably with “culture supernatant”, “conditioned culture medium” or “conditioned medium”, and may mean the entire medium including the strain, its metabolites, extra nutrients, etc., obtained by culturing the strain for a certain period of time in a medium capable of supplying nutrients so that Bifidobacterium longum can grow and survive in a test tube.
  • the culture medium may mean a culture medium obtained by culturing the strain and removing the bacterial cells from the bacterial cell culture.
  • the liquid from the culture medium from which the bacterial cells have been removed is also called a "supernatant", and may be obtained by allowing the culture medium to stand still for a certain period of time and taking only the liquid in the upper layer excluding the portion that has settled to the lower layer, removing the bacterial cells through filtration, or centrifuging the culture medium to remove the sediment at the lower layer and taking only the liquid at the upper layer.
  • the above “mycelia” refers to the strain of the present invention itself, and includes the strain itself selected by separating from a skin sample or the like, or the strain separated from the culture solution by culturing the strain.
  • the mycelia can be obtained by centrifuging the culture solution and taking the portion that has settled to the lower layer, or by allowing the mycelia to settle to the lower layer of the culture solution by gravity and then leaving it alone for a certain period of time and then removing the upper liquid.
  • the above culture solution may include the culture solution itself, a concentrate thereof, or a lyophilized product obtained by culturing the strain, or a culture supernatant obtained by removing the strain from the culture solution, a concentrate thereof, or a lyophilized product thereof.
  • the above culture solution may be obtained by culturing Bifidobacterium longum in an appropriate medium (e.g., R2A medium or TSA medium) at a temperature of more than 10°C or less than 40°C for a certain period of time, for example, 4 to 50 hours.
  • an appropriate medium e.g., R2A medium or TSA medium
  • the culture supernatant of the strain can be obtained by a step of removing the strain by centrifuging or filtering the strain culture solution.
  • the concentrate can be obtained by a step of concentrating the strain culture itself, or the supernatant obtained after filtering the culture using centrifugation or a filter.
  • the culture medium and culture conditions for culturing the above Bifidobacterium longum can be appropriately selected or modified by a person of ordinary skill in the art.
  • disruption solution in this specification may mean a product obtained by disrupting the cell wall of the strain itself by chemical or physical force.
  • culture solution extract in this specification means an extract from the culture solution or a concentrate thereof, and may include an extract, a dilution or concentrate of the extract, a dried product obtained by drying the extract, or a adjusted or purified product thereof, or a fraction obtained by fractionating the same.
  • the composition is present in an amount of 0.00001 wt% to 80 wt%, for example, 0.00001 wt% to 60 wt%, 0.00001 wt% to 40 wt%, 0.00001 wt% to 30 wt%, 0.00001 wt% to 20 wt%, 0.00001 wt% to 10 wt%, 0.00001 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt%, 0.05 wt% to 20 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 5 wt%, 0.1 wt% to 60 wt%, 0.1 wt% to 40 wt%, 0.1 It may comprise from 0.1 wt % to 30 wt %, from 0.1 wt % to 20 wt%, from 0.1 w
  • the term, "including as an active ingredient” means that the strain of the present specification, vesicles derived from the strain, a lysate of the strain, a culture medium, or an extract of the culture medium thereof are added to an extent capable of exhibiting the effects mentioned above, and includes formulation in various forms by adding various components as auxiliary components for drug delivery and stabilization, etc.
  • the composition may be a pharmaceutical composition.
  • the pharmaceutical composition may additionally comprise a pharmaceutically acceptable diluent or carrier.
  • the diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the glidant may be magnesium stearate, talc, or a combination thereof.
  • the carrier may be an excipient, a disintegrant, a binder, a glidant, or a combination thereof.
  • the excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof.
  • the disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium dihydrogen phosphate, or a combination thereof.
  • the binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof.
  • the glidant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.
  • the pharmaceutical composition may be formulated as an oral or parenteral dosage form.
  • the oral dosage form may be a granule, a powder, a liquid, a tablet, a capsule, a dry syrup, or a combination thereof.
  • the parenteral dosage form may be an injection.
  • the above composition may be a health functional food composition.
  • the above health functional food composition can be used alone or in combination with the strain or its culture solution or with other foods or food ingredients, and can be used appropriately according to a conventional method.
  • the amount of the active ingredient mixture can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment).
  • the composition of the present specification can be added in an amount of 15 parts by weight or less to the raw material.
  • the beverage composition can contain various flavoring agents or natural carbohydrates as additional ingredients, like a conventional beverage.
  • the natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • a natural sweetener such as thaumatin and stevia extract, or a synthetic sweetener such as saccharin and aspartame can be used.
  • the above health food composition may also contain nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, or a combination thereof.
  • the above health functional food composition may also contain fruit pulp for the production of natural fruit juice, fruit juice drinks, vegetable drinks, or a combination thereof.
  • the above composition may be a cosmetic composition.
  • the above cosmetic composition may have, for example, a cosmetic formulation of a flexible toner, a nourishing toner, a massage cream, a nourishing cream, an essence, a pack, a gel, an ampoule or a skin adhesive type.
  • ingredients included in the above cosmetic composition may include ingredients commonly used in cosmetic compositions in addition to the composition as an effective ingredient, and may include, for example, conventional auxiliary agents and carriers such as stabilizers, solubilizers, vitamins, pigments, and fragrances.
  • composition may be a composition for external use on the skin.
  • the skin external preparation may be a cream, a gel, an ointment, a skin emulsifier, a skin suspension, a transdermal patch, a drug-containing bandage, a lotion, or a combination thereof.
  • the skin external preparation may be appropriately mixed with ingredients commonly used in skin external preparations such as cosmetics or medicines, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof, as needed.
  • the above skin external preparation may also appropriately contain metal sequestrants such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannin, bellapamil, licorice extract, glablidine, hot water extract of the fruit of Kalin; various crude drugs; tocopheryl acetate, glycyrrhizic acid, tranexamic acid and derivatives or salts thereof; and sugars such as vitamin C, magnesium ascorbic acid phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.
  • metal sequestrants such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid
  • caffeine tannin, bellapamil, licorice extract, glablidine, hot water extract of the fruit of Kalin
  • various crude drugs tocopheryl
  • Another aspect provides the use of the composition described above for the manufacture of a pharmaceutical preparation for the prevention or treatment of allergic diseases.
  • Another aspect provides a method of preventing, ameliorating, or treating a condition of a subject comprising the step of treating or administering to a subject in need thereof an effective amount of the composition as described above.
  • the condition of the above entity may be related to an allergic disease.
  • the allergic disease is as described above.
  • Administration can be by any method known in the art. Administration can be directly administered to the subject by any means, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. The administration can be systemic or local.
  • the subject may be a mammal, for example, a human, a cow, a horse, a pig, a dog, a sheep, a goat, or a cat.
  • the subject may be an individual in need of an effect of improving a condition related to an allergic disease.
  • the allergic disease is as described above.
  • the above administration is in an amount of 0.00001 mg to 1,000 mg per subject per day, for example, 0.00001 mg to 500 mg, 0.00001 mg to 100 mg, 0.00001 mg to 50 mg, 0.00001 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, Or it may be administered 10 mg to 25 mg.
  • the dosage may be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a person skilled in the art can appropriately adjust the dosage considering these factors.
  • the number of administrations can be once a day or twice or more within the range of clinically acceptable side effects, and the administration site can be administered to one or more sites, and the total number of administration days can be from 1 day to 30 days for one treatment, daily or at intervals of 2 to 5 days. If necessary, the same treatment can be repeated after an appropriate period.
  • the same dosage as for humans per kg can be administered, or the amount converted from the above dosage can be administered based on the volume ratio (e.g., average value) of the organs (heart, etc.) of the target animal and the human.
  • the strain according to the daily aspect and the composition containing the strain as an effective ingredient it can be effectively used for the prevention, improvement, and treatment of allergic diseases.
  • Figure 1 shows changes in immune cells upon strain treatment according to one specific example
  • PBS negative control
  • Alum positive control
  • Bifidobacterium longum experimental group.
  • Figure 2 is a graph showing changes in cytokines in bronchoalveolar lavage fluid when treated with a strain according to one specific example; PBS: negative control, Alum: positive control, Bifidobacterium longum: experimental group.
  • Figure 3 is a graph showing the change in the total amount of three types of antibodies (IgE, IgG1, and IgG2c) and the amount of ovalbumin-specific antibody IgE when treating the strain according to one specific example in serum; PBS: negative control group, Alum: positive control group, Bifidobacterium longum: experimental group.
  • Figure 4 is a graph showing changes in inflammatory cell infiltration in lung tissue upon strain treatment according to one specific example; PBS: negative control group, Alum: positive control group, Bifidobacterium longum: experimental group.
  • Bifidobacterium longum deposited under the name KCTC14523BP was prepared as follows.
  • the strain was cultured in MRS broth (DeMan-Rogosa-Sharpe, MB Cell) at 37°C under anaerobic conditions for 2 days. Afterwards, the culture solution was centrifuged at 5000 xg for 20 minutes to remove bacterial debris. Afterwards, it was dispensed into clean MRS broth at 1x109 CFU/ml and stored in an ultra-low temperature freezer for use in the experiment.
  • MRS broth DeMan-Rogosa-Sharpe, MB Cell
  • mice To induce an animal model of eosinophilic asthma, 7-8 week old mice were used. On days 0 and 7, a mixture of LPS-free ovalbumin and aluminum hydroxide was administered intraperitoneally to induce immune memory to ovalbumin. On days 14, 15, 21, and 22, after anesthetizing the mice, ovalbumin alone was administered intranasally to induce airway inflammation.
  • Example 1 After exposure to ovarian albumin in the nasal cavity, the strain of Example 1 was administered orally once a day for a total of 7 days on days 14 to 19, 21, and 22 to the experimental group.
  • the strain administration dose was 1X109 CFU/mouse per time.
  • mice were dissected to obtain samples for the experiment.
  • the obtained samples were bronchoalveolar lavage fluid, blood, and lung tissue.
  • the mouse dissection was started by anesthetizing the mouse using an animal anesthetic, and then making an incision from the neck to the abdominal cavity.
  • the diaphragm was removed and heart blood collection was performed.
  • For bronchoalveolar lavage fluid an IV catheter was connected to the trachea, inserted, and a 1 ml syringe containing cooled and sterile PBS was connected. By the method of injecting into the trachea and then recovering. Bronchoalveolar lavage fluid (BAL fluid) was obtained, washed twice with 1 ml, and this was repeated twice.
  • BAL fluid Bronchoalveolar lavage fluid
  • lung tissue perfusion was performed from the heart using a 5 ml syringe and 1x PBS to remove any remaining blood in the lung tissue, and the lung tissue was excised, frozen, and fixed in 4% formaldehyde to obtain it. These were used in the following experimental examples.
  • the effect of the strain of Example 1 on alleviating the influx of inflammatory cells into the bronchoalveolar lavage fluid was analyzed.
  • the immune cells influx into the bronchoalveolar lavage fluid during airway inflammation and the effect of the strain of Example 1 on reducing airway inflammation were analyzed.
  • mice sensitized intranasally with ovamin alone (positive control group) and mice administered with strain (experimental group) were prepared using the method of Example 2.
  • bronchoalveolar lavage fluid Analysis of bronchoalveolar lavage fluid was conducted as follows. First, the obtained bronchoalveolar lavage fluid was centrifuged to separate cells and supernatant. After collecting cells, RBCs (red blood cells) were removed, and the number and type of cells were analyzed.
  • RBCs red blood cells
  • the test was performed a total of three times, and the results of each experiment were added together to perform a comparative analysis.
  • Figure 1 shows changes in immune cells upon strain treatment according to one specific example
  • PBS negative control
  • Alum positive control
  • Bifidobacterium longum experimental group.
  • strain according to one specific example can be useful for preventing, improving, or treating allergic diseases, inflammatory respiratory diseases, asthma, allergic asthma, eosinophilic asthma, or eosinophilia.
  • the effect of the strain of Example 1 on alleviating cytokine production in bronchoalveolar lavage fluid was analyzed.
  • mice negative control group
  • nasal sensitized mice with ovalbumin alone positive control group
  • strain-administered mice experimental group
  • the cytokines that increase during airway inflammation in bronchoalveolar lavage fluid and the effect of the strain of Example 1 on alleviating cytokine production were analyzed.
  • mice sensitized intranasally with ovamin alone (positive control group) and mice administered with strain (experimental group) were prepared using the method of Example 2.
  • bronchoalveolar lavage fluid The analysis of bronchoalveolar lavage fluid was conducted as follows. First, the obtained bronchoalveolar lavage fluid was centrifuged to separate cells and supernatant. After taking the supernatant, the amount of cytokine production and changes were evaluated through sandwich ELISA and colorimetric analysis. The evaluation items were IL-4, IL-5, IL-13, and Eotaxin, and the entire bronchoalveolar lavage fluid obtained after three repeated tests was analyzed.
  • Figure 2 is a graph showing changes in cytokines in bronchoalveolar lavage fluid when treated with a strain according to one specific example; PBS: negative control, Alum: positive control, Bifidobacterium longum: experimental group.
  • the four cytokines that increased were IL-4 and IL-13, which are important cytokines for Th2 cell differentiation and immune response, and IL-5 and Eotaxin, which are important cytokines for eosinophil generation and migration.
  • strain according to one specific example can effectively reduce the production of IL-4 or IL-13 or Th2 cell differentiation in allergic diseases, inflammatory respiratory diseases, asthma, allergic asthma, eosinophilic asthma, or eosinophilia.
  • the strain according to one specific example can effectively reduce the production of IL-5, Eotaxin or eosinophils in allergic diseases, inflammatory respiratory diseases, asthma, allergic asthma, eosinophilic asthma or eosinophilia.
  • strain according to one specific example can be useful for preventing, improving, or treating allergic diseases, inflammatory respiratory diseases, asthma, allergic asthma, eosinophilic asthma, or eosinophilia.
  • Example 1 The effect of the strain of Example 1 on alleviating antibody production in serum was analyzed.
  • a comparative experiment was conducted using mice administered PBS (negative control group), mice intranasally sensitized with ovalbumin alone (positive control group), and mice administered the strain (experimental group).
  • mice sensitized intranasally with ovamin alone (positive control group) and mice administered with strain (experimental group) were prepared using the method of Example 2.
  • Serum analysis was conducted as follows. Blood was obtained by the method of Example 1, and then centrifuged to separate the serum. The production and changes in total antibodies and ovalbumin-specific antibodies in the separated serum were analyzed using sandwich ELISA, indirect ELISA, and colorimetric analysis. The evaluation items were three types of antibodies (IgE, IgG1, and IgG2c), and all serum samples in the experiment were evaluated.
  • Figure 3 is a graph showing the change in the total amount of three types of antibodies (IgE, IgG1, and IgG2c) and the amount of ovalbumin-specific antibody IgE when treating the strain according to one specific example in serum; PBS: negative control group, Alum: positive control group, Bifidobacterium longum: experimental group.
  • strain according to one specific example can effectively reduce the total amount of antibodies and the production of antigen-specific IgE antibodies introduced into the serum during airway inflammation.
  • strain according to one specific example can be useful for preventing, improving, or treating allergic diseases, inflammatory respiratory diseases, asthma, allergic asthma, eosinophilic asthma, or eosinophilia.
  • mice administered PBS negative control group
  • mice nasally sensitized with ovalbumin alone positive control group
  • mice administered the strain experimental group
  • mice sensitized intranasally with ovamin alone (positive control group) and mice administered with strain (experimental group) were prepared using the method of Example 2.
  • inflammatory cell infiltration in lung tissue was conducted as follows. First, fixed lung tissue was sectioned at 4 ⁇ cM and stained with hematoxylin and eosin. Using an optical microscope, inflammation in the tissue was identified (peri-vascular, peri-bronchial region) and quantified according to the degree, and then compared and analyzed to compare the degree of inflammatory cell infiltration.
  • Figure 4 is a graph showing changes in inflammatory cell infiltration in lung tissue upon strain treatment according to one specific example; PBS: negative control group, Alum: positive control group, Bifidobacterium longum: experimental group.
  • strain according to one specific example can be useful for preventing, improving, or treating allergic diseases, inflammatory respiratory diseases, asthma, allergic asthma, eosinophilic asthma, or eosinophilia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition contenant Bifidobacterium longum comme principe actif pour la prévention ou le traitement de maladies allergiques. Dans un aspect, la souche peut être utilisée efficacement dans la prévention, l'atténuation et/ou le traitement de maladies allergiques, de maladies respiratoires inflammatoires, de l'asthme, de l'asthme allergique, de l'asthme éosinophilique et/ou de l'éosinophilie, par diminution de l'afflux de cellules inflammatoires, réduction de la production de cytokines, atténuation de la génération d'anticorps et soulagement de l'infiltration de cellules inflammatoires.
PCT/KR2024/001823 2023-02-07 2024-02-07 Composition contenant bifidobacterium longum comme principe actif et servant à la prévention ou au traitement de maladies allergiques Ceased WO2024167307A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2023-0016389 2023-02-07
KR1020230016389A KR102568093B1 (ko) 2023-02-07 2023-02-07 비피도박테리움 롱검을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2024167307A1 true WO2024167307A1 (fr) 2024-08-15

Family

ID=87799421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2024/001823 Ceased WO2024167307A1 (fr) 2023-02-07 2024-02-07 Composition contenant bifidobacterium longum comme principe actif et servant à la prévention ou au traitement de maladies allergiques

Country Status (2)

Country Link
KR (1) KR102568093B1 (fr)
WO (1) WO2024167307A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119144530A (zh) * 2024-11-21 2024-12-17 青岛诺和诺康生物科技有限公司 长双歧杆菌长亚种及其改善哮喘及高组胺水平的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102568093B1 (ko) * 2023-02-07 2023-08-22 주식회사 바이오뱅크힐링 비피도박테리움 롱검을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물
KR20250112349A (ko) 2024-01-16 2025-07-24 서울대학교산학협력단 신규 비피도박테리움 롱검 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9644210B2 (en) * 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
KR20180089324A (ko) * 2017-01-31 2018-08-08 경희대학교 산학협력단 신규 유산균 및 이의 용도
KR102351145B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102568093B1 (ko) * 2023-02-07 2023-08-22 주식회사 바이오뱅크힐링 비피도박테리움 롱검을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101778734B1 (ko) 2016-03-11 2017-09-18 대한민국(농촌진흥청장) 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9644210B2 (en) * 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
KR20180089324A (ko) * 2017-01-31 2018-08-08 경희대학교 산학협력단 신규 유산균 및 이의 용도
KR102351145B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102568093B1 (ko) * 2023-02-07 2023-08-22 주식회사 바이오뱅크힐링 비피도박테리움 롱검을 유효성분으로 포함하는 알레르기 질환의 예방 또는 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM JEON-KYUNG, KIM JAE-YOUNG, KIM HYE IN, HAN MYUNG JOO, KIM DONG-HYUN: "Bifidobacterium longum and Lactobacillus plantarum alleviate house dust mite allergen-induced allergic rhinitis by regulating IL-4, IL-5, and IL-10 expression", FOOD AND AGRICULTURAL IMMUNOLOGY., TAYLOR & FRANCIS, GB, vol. 30, no. 1, 1 January 2019 (2019-01-01), GB , pages 581 - 593, XP093198655, ISSN: 0954-0105, DOI: 10.1080/09540105.2019.1608161 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119144530A (zh) * 2024-11-21 2024-12-17 青岛诺和诺康生物科技有限公司 长双歧杆菌长亚种及其改善哮喘及高组胺水平的应用

Also Published As

Publication number Publication date
KR102568093B1 (ko) 2023-08-22

Similar Documents

Publication Publication Date Title
WO2024167307A1 (fr) Composition contenant bifidobacterium longum comme principe actif et servant à la prévention ou au traitement de maladies allergiques
KR102337998B1 (ko) 로제부리아 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2012165843A2 (fr) Composition comprenant des extraits d'herbes ou leurs produits fermentés qui comportent des bactéries d'acide lactique, dans la prévention ou le traitement de maladies respiratoires
KR102539776B1 (ko) 홀데마넬라 바이포미스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2018030732A1 (fr) Nanovésicules dérivées de bactéries du genre bacillus et leur utilisation
KR102539772B1 (ko) 락토코커스 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102337993B1 (ko) 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2018105926A1 (fr) Composition anti-allergique contenant un extrait d'herbe médicinale composite fermenté par des lactobacilles à titre de principe actif
WO2019172668A1 (fr) Nouvelle utilisation d'extrait de maydis stigma dans la prophylaxie et la thérapie d'un trouble du sommeil
KR102365420B1 (ko) 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102337991B1 (ko) 코프로코커스 유탁터스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023014048A1 (fr) Souche de bifidobactérium ou pediococcus sp. et les vésicules qui en sont dérivées, et leurs utilisations anti-inflammatoires et antibactériennes
CN120459170A (zh) 一种益生菌组合物在制备预防和/或治疗肺炎药物中的应用
WO2021242056A1 (fr) Souche de l'espèce bifidobacterium et vésicule extracellulaire dérivée de cette dernière, et leurs utilisations anti-inflammatoires et antibactériennes
WO2021261929A1 (fr) Nouvelle souche de lactobacillus reuteri et utilisation associée
KR102620189B1 (ko) 블라우티아 브룩킹시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102438867B1 (ko) 코프로코커스 캐터스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102444328B1 (ko) 아나에로스티페스 하드루스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2019245225A1 (fr) Composition permettant d'améliorer la fonction intestinale comprenant une souche leuconostoc sp.
WO2023234587A1 (fr) Souche de veillonella seminalis, milieu de culture dérivé de celle-ci et utilisations anti-inflammatoires de ceux-ci
US20240335481A1 (en) Blautia sp. strain, leuconostoc sp. strain, or ruminococcus sp. strain and endoplasmic reticulum derived therefrom, and anti-inflammatory and antibacterial uses thereof
KR102331485B1 (ko) 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331486B1 (ko) 비피도박테리움 슈도카테눌라튬 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2021242057A1 (fr) Souche de lactobacillus sp., reticulum endoplasmique dérivé de cette dernière, et utilisation anti-inflammatoire et antibactérienne associée
WO2023022473A1 (fr) Composition comprenant une vésicule extracellulaire dérivée de cellules souches en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24753629

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE